ABO blood group incompatibility: A diminishing barrier to successful kidney transplantation?

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 893-900

  Kahwaji, Joseph ^a   Vo, Ashley A ^a   Jordan, Stanley C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

ABO incompatible; B cell; IVIg; kidney transplantation; plasmapheresis; rituximab

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BLOOD GROUP A ANTIBODY; BLOOD GROUP ANTIGEN; BLOOD GROUP B ANTIBODY; BORTEZOMIB; CD20 ANTIGEN; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FC RECEPTOR; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEASOME INHIBITOR; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN SPECIFIC IMMUNOADSORPTION; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DESENSITIZATION; DOUBLE FILTRATION PLASMAPHERESIS; DRUG TARGETING; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PLASMAPHERESIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SPLENECTOMY;

ABO BLOOD-GROUP SYSTEM; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; KIDNEY TRANSPLANTATION; PLASMA EXCHANGE; TRANSPLANTATION CONDITIONING;

EID: 78049426078     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.78     Document Type: Review

References (53)

1. Imamura R, Ishiguro S, Shi Y et al. ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report. Xenotransplantation 13(2), 133-135 (2006).
2. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy Am. J. Transplant. 4(8), 1315-1322 (2004).
3. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl. Int. 22(4), 447-454 (2009).
4. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specifc immunoadsorption and rituximab. Am. J. Transplant. 5(1), 145-148 (2005).
5. Squiffet J, De Meyer M, Malaise J, Latinne D, Pirson Y, Alexandre G. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp. Clin. Transplant. 2(1), 208-213 (2004).
6. Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 87(8), 1246-1255 (2009).
7. Stegall M, Dean P, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am. J. Transplant. 9(5), 998-1005 (2009).
8. Matter M, Ochsenbein A. Natural antibodies target virus-antibody complexes to organized lymphoid tissue. Autoimmun. Rev. 7(6), 480-486 (2008).
9. Paul L, van Es L, Riviere G, Eernisse G, de Graeff J. Blood group B antigen on renal endothelium as the target for rejection in an ABO-incompatible recipient. Transplantation 26(4), 268-271 (1978).
10. Tobian A, Shirey R, Montgomery R, Ness P, King K. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 48(11), 2453-2460 (2008).
11. Hume D, Merrill J, Miller B, Thorn G. Experiences with renal homotransplantation in the human: report of nine cases. J. Clin. Invest. 34(2), 327-382 (1955).
12. Tanabe K, Takahashi K, Agishi T, Toma H, Ota K. Removal of anti-A/B antibodies for successful kidney transplantation between ABO blood type incompatible couples. Transfus. Sci. 17(3), 455-462 (1996).
13. Aeschbacher B, Wiedmer W, Stuck A, Gaenger K, Frey F, Nydegger U. [Immunoadsorption of anti-B antibodies as preparation for an ABO-incompatible kidney transplantation]. Schweiz. Med. Wochenschr. 117(19), 716-722 (1987).
14. Raja R, Bannett A, Caruana R, Baquero A. Removal of antibodies with immunoadsorption from an ABO incompatible recipient prior to renal transplant. ASAIO Trans. 32(1), 102-103 (1986).
15. Thaiss F. Specifc issues in living donor kidney transplantation: ABO-incompatibility. Atheroscler. Suppl. 10(5), 133-136 (2009).
16. Mendez R, Sakhrani L, Chaballout A, Mendez R. ABO incompatible transplants involving A2 donors. Transplant. Proc. 23(2), 1738-1741 (1991).
17. Alexandre GP, Squiffet JP, De Bruyere M et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant. Proc. 19(6), 4538-4542 (1987).
18. Tanabe K, Takahashi K, Sonda K et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 65(2), 224-228 (1998). (Pubitemid 28101328)
19. Toki D, Ishida H, Horita S, Yamaguchi Y, Tanabe K. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation 88(10), 1186-1193 (2009).
20. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 84(12 Suppl.), S4-S7 (2007).
21. Mannami M, Mitsuhata N. Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation 79(12), 1756-1758 (2005).
22. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev. Immunol. 6(5), 394-403 (2006).
23. Salama AD, Pusey CD. Drug insight: rituximab in renal disease and transplantation. Nat Clin. Pract Nephrol. 2(4), 221-230 (2006).
24. Kahwaji J, Tong C, Jordan S, Vo A. Rituximab: an emerging therapeutic agent for kidney transplantation. Transplant Res. Risk Manage. 1, 15-29 (2009).
25. Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans. Am. Clin. Climatol. Assoc. 117, 199-211; discussion 211 (2006).
26. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 84(12 Suppl.), S33-S36 (2007).
27. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am. J. Transplant. 7(2), 402-407 (2007).
28. Sidner R, Book B, Agarwal A, Bearden C, Vieira C, Pescovitz M. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum. Antibodies 13(3), 55-62 (2004).
29. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56(9), 3044-3056 (2007).
30. + B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation 87(9), 1394-1401 (2009).
31. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-fltration plasmapheresis. Transplantation 74(9), 1207-1210 (2002).
32. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specifc immunoadsorption and rituximab. Transplantation 76(4), 730-731 (2003).
33. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO-incompatible kidney transplantation and rituximab. Transplant. Proc. 37(8), 3286-3287 (2005).
34. Villicana R. ABO incompatible kidney transplantation using rituximab, pre-transplant plasmapheresis followed by high dose IVIG: a single center experience. Am. J. Transplant. 9(Suppl. 2), 560 (2009).
35. Genberg H, Kumlien G, Wennberg L, Tydén G. Long-term results of ABO-incompatible kidney transplantation with antigen-specifc immunoadsorption and rituximab. Transplantation 84(12 Suppl.), S44-S47 (2007).
36. Tydén G, Donauer J, Wadström J et al. Implementation of a protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 83(9), 1153-1155 (2007).
37. Wilpert J, Fischer K, Pisarski P et al. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specifc desensitization. An observational comparative analysis. Nephrol. Dial. Transplant. DOI: 10.1093/ndt/gfq229 (2010) (Epub ahead of print).
38. Toki D, Ishida H, Setoguchi K et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am. J. Transplant. 9(3), 567-577 (2009).
39. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib. Nephrol. 162, 61-74 (2009).
40. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 89(12), 1466-1470 (2010).
41. Segev D, Simpkins C, Warren D et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am. J. Transplant. 5(10), 2570-2575 (2005).
42. Montgomery R, Locke J. ABO-incompatible transplantation: less may be more. Transplantation 84(12 Suppl.), S8-S9 (2007).
43. Kahwaji J, Toyoda M, Reinsmoen N et al. Infectious complications associated with rituximab for desensitization protocols. Am. J. Transplant 10(Suppl. 4), 170 (2010).
44. Reding R, Squiffet J, Latinne D, De Bruyère M, Pirson Y, Alexandre G. Early postoperative monitoring of natural anti-A and anti-B isoantibodies in ABO-incompatible living donor renal allografts. Transplant Proc. 19(1 Pt 3), 1989-1990 (1987).
45. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77(4), 542-548 (2004).
46. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specifc immunoadsorption and rituximab: a 3-year follow-up. Transplantation 85(12), 1745-1754 (2008).
47. Oppenheimer F, Revuelta I, Serra N et al. [ABO incompatible living donor kidney transplantation: a dream come true. Experience of Hospital Clínic of Barcelona]. Nefrologia 30(1), 54-63 (2010).
48. Vo AA, Wechsler EA, Wang J et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am. J. Transplant 8(1), 144-149 (2008).
49. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl. J. Med. 359(3), 242-251 (2008).
50. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant. Proc. 40(7), 2218-2221 (2008).
51. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am. J. Transplant. 8(12), 2607-2617 (2008).
52. Haas M. The signifcance of C4d staining with minimal histologic abnormalities. Curr. Opin Organ Transplant. 15(1), 21-27 (2010).
53. Stasi R, Cooper N, Del Poeta G et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112(4), 1147-1150 (2008).